Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.

Although it represented only <0.1% of the total proportion of CD4 + T cells, this rare circulating subset producing all four cytokines (IFNγ + , IL-17A + , GM-CSF + , IL-2 + ) showed a modest reduction as early as 12 weeks and a highly significant ( P < 0.001) reduction at weeks 28 and 52 after the start of therapy (Fig. 3d,h ).

also in 132,142 other papers

After imputation 10×, the geometric ratio of ustekinumab to control changed to 1.36 (95% CI = 0.81, 1.63; P = 0.27) and did not reach statistical significance.

also in 111,027 other papers